---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-067136"
form_type: "8-K"
ticker: "CBLL"
cik: "0001861107"
company_name: "Ceribell, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:53:22.331487+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ceribell Q4 revenue $24.8M (+34% YoY); FY 2026 guidance $111-115M

## Summary
- Full-year 2025 revenue $89.1M (+36% YoY); net loss $53.4M ($1.46/share).
- Q4 gross margin 87%; active accounts 647; cash $159.3M.
- FY 2026 revenue guidance $111-115M, representing 25-29% growth.
- FDA 510(k) clearance for continuous delirium monitoring and neonatal seizure detection.
- FDA Breakthrough Device Designation for large vessel occlusion stroke detection solution.

## SEC filing metadata
- accession: 0001193125-26-067136
- form_type: 8-K
- ticker: CBLL
- cik: 0001861107
- company_name: Ceribell, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861107/000119312526067136/0001193125-26-067136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861107/000119312526067136/cbll-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-067136
- JSON: https://secwatch.observer/filing/0001193125-26-067136.json
- Plain text: https://secwatch.observer/filing/0001193125-26-067136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.